Table I.
mRNA expression levels of MRP1 and MRP3 prior to and following TMZ intervention for 24 h.
| Cell type | No intervention | 50 µmol/l | 100 µmol/l | 200 µmol/l | 400 µmol/l |
|---|---|---|---|---|---|
| MRP1 (x10−4) | |||||
| ACC | 4.570±0.410 | 6.161±0.693c | 6.688±0.809c | 7.232±0.820d | 7.848±1.006d |
| ACC siRNA | 6.315±0.522a | 4.678±0.240d,a | 4.354±0.438d,a | 4.094±0.187d,b | 2.703±0.182d,b |
| GSC | 5.527±0.528 | 7.287±0.902c | 8.058±0.765d | 8.818±0.977d | 13.108±1.478d |
| GSC siRNA | 9.074±0.746b | 6.861±0.640c | 4.351±0.472d,b | 3.610±0.269d,b | 3.399±0.297d,b |
| MRP3 (x10−4) | |||||
| ACC | 25.419±4.272 | 31.101±3.002 | 27.615±3.946 | 17.894±1.963c | 14.365±1.789c |
| ACC siRNA | 23.384±2.879 | 25.819±2.834 | 22.650±1.424 | 19.781±1.840 | 17.631±1.798c |
| GSC | 7.614±0.748 | 9.605±0.722c | 10.798±1.350c | 12.616±1.084d | 17.464±1.658d |
| GSC siRNA | 19.537±0.923b | 15.704±1.322c,b | 21.469±1.949b | 24.638±1.056d,b | 28.448±2.504d,b |
Results are expressed as the mean ± standard deviation.
a
P<0.05
b
P<0.01, vs. control group of the same cells at the same concentration
c
P<0.05
d
P<0.01, vs. same cells without any intervention. ACC, autologous cancer cell; GSC, glioma stem cell; MRP, multidrug resistance-associated protein; TMZ, temozolomide.